Virology

COVID-19

Identify the deaminase source of mutations that potentially inactivate the virus, and may result in new viral strains.

Define the specific COVID-19 deaminase binding sites that can potentially be new drug 'pockets'.

THE CONTRIBUTION WE WILL MAKE TO THE COVID-19 RESPONSE

GMDx IIF profiling tools are immediately available to reveal new insights into COVID-19.

Chronic Hepatitis B (cHBV)

Established the Innate Immune Profile Score that:

  • Identify patients who can safely stop antiviral therapy

  • Identify patients who should remain on antiviral therapy due to a high likelihood of relapse (i.e. with compromised innate immune system)

Flavivirus Host-Parasite Study

GMDx was the first to show that the host virus relationship is characterised by the host's deaminase-associated mutations hat attack viruses - and give rise to viral strain diversity.

LEGAL

© 2020 GMDx Genomics. All rights reserved.